Key result
Obesity in T2DM is linked to ~56% lower serum omentin levels versus non-obese patients.
Why the study?
The clinical, diagnostic, and prognostic value of omentin levels in type 2 diabetes mellitus combined with excess body weight and obesity remained to be evaluated.
Does the presence of excess body weight and obesity affect omentin levels in patients with type 2 diabetes mellitus?
Cross-Sectional (n=126)
No
Does the presence of excess body weight and obesity affect omentin levels in patients with type 2 diabetes mellitus?
Effect estimate: 127.48% difference
Absolute Event Rate: 8.08% vs 18.38%
p-value: p=<0.05
Omentin levels are significantly reduced in patients with type 2 diabetes and obesity, and further decrease with poor glycemic control, longer disease duration, and higher cardiovascular risk.
Lower omentin in obese T2DM patients should not yet change practice; leaves open its role as CV risk biomarker.
Type 2 diabetes mellitus (DM) is a heterogeneous disease characterized by a complex of metabolic disorders, the main features of which are insulin resistance and insufficient of pancreatic cell function of varying severity.Objective — to study the clinical, diagnostic and prognostic value of the level of omentin in type 2 diabetes mellitus in combination with excess body weight (EBW) and obesity.Material and methods. 98 people with diabetes mellitus were examined, the first group consisted of 64 people with EBW and obesity (body mass index > 25). The second group consisted of 34 people with type 2 diabetes mellitus and normal body weight (body mass index ≤ 25). As a control, a group of 28 practically healthy individuals were examined, which were comparable to the first and second groups by gender and age.Results. The presence of type 2 diabetes, EBW and obesity in patients leads to a decrease in the marker of compensation for impaired metabolism of carbohydrates, lipids and a decrease in insulin resistance — omentine by 127.48% relative to patients with type 2 diabetes without EBW and obesity. Patients with glycated hemoglobin HbA1c values of more than 8% showed a decrease in omentin values compared with patients with compensated diabetes, the difference was more pronounced in patients with EBW and obesity (28.29%, p<0.05), in the absence of EBW and obesity the difference was 13.66%. An increase in the duration of type 2 DM led to a depression of the studied marker of omentin in patients with obesity by 39.24% (p<0.05), in the absence of obesity — by 25.95%. The development of the complicated course of type 2 DM in patients with obesity led to a decrease in the values of omentin by 51.09% (p<0.05), in the absence of obesity — by 13.39%. A high and very high cardiovascular risk in patients with type 2 DM with obesity led to a difference in omentine values by 39.48% (p <0.05) in favor of high risk, and in patients without obesity — by 25.66%.Conclusion. Omentin levels in type 2 diabetes mellitus depend on the presence of excess body weight and obesity in patients and on the characteristics of the clinical course of comorbidity, decreasing with the development of decompensation and complications.
No takes yet. Share an insight, caveat, or question.
О. A. Solovyuk (2020) conducted a cross-sectional in Type 2 diabetes mellitus and obesity (n=126). Excess body weight and obesity (BMI > 25) vs. Normal body weight (BMI ≤ 25) and healthy controls was evaluated on Serum omentin concentration (ng/ml) (127.48% difference, p=<0.05). The presence of excess body weight and obesity in patients with type 2 diabetes mellitus was associated with significantly lower serum omentin levels (8.08 ng/ml) compared to patients without obesity (18.38 ng/ml).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: